跳到主要內容

臺灣博碩士論文加值系統

(44.211.24.175) 您好!臺灣時間:2024/11/13 08:06
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

: 
twitterline
研究生:黃國棟
研究生(外文):Huang Kuo-Tong
論文名稱:探討Dipyridamole在anti-Thy-1抗體引發腎絲球腎炎動物模式中的抗發炎功能
論文名稱(外文):The anti-inflammatory effects of Dipyridamole in anti-Thy-1 antibody induced Glomerulonephritis
指導教授:李宏謨李宏謨引用關係洪冠予洪冠予引用關係
指導教授(外文):Lee Horng-MoHung Kuan-Yu
學位類別:碩士
校院名稱:臺北醫學大學
系所名稱:醫學技術學系
學門:醫藥衛生學門
學類:醫學技術及檢驗學類
論文種類:學術論文
論文出版年:2007
畢業學年度:95
語文別:中文
論文頁數:90
中文關鍵詞:腎絲球腎炎抗發炎功能
外文關鍵詞:Dipyridamoleanti-Thy-1 antibodyglomerulonephritis
相關次數:
  • 被引用被引用:0
  • 點閱點閱:311
  • 評分評分:
  • 下載下載:4
  • 收藏至我的研究室書目清單書目收藏:1
Anti-thy-1 抗體所引發的腎絲球腎炎,是一種常被引用來研究腎環門間質細胞( Mesangial cell )增生性腎絲球腎炎的動物模式。Dipyridamole是一種phosphodiesterase抑制劑,臨床上曾被用來治療由絲球體腎炎所引起的蛋白尿。然而,Dipyridamole於臨床上的治療機制目前尚未完全明瞭。由實驗室先前的研究顯示;發現到,施打anti-Thy-1抗體所引發的急性腎絲球腎炎,其症狀會出現明顯蛋白尿、ED(+)巨噬細胞移行、浸潤、及中度的PCNA(+)細胞增生。以上這些症狀經由Dipyridamole( 5mg/kg )治療的大鼠實驗可明顯觀察到抑制情形。TGF-β對於調控細胞外基質-collegen、fibronectin的分泌具重要的關鍵。我們也測試了Dipyridamole對於TGF-β表現和細胞間質增生、堆積的抑制,是否有相同的效果。由PAS score增加顯示;經由施打anti-Thy-1抗體所引發的少量腎絲球TGF-β增生和細胞基質堆積,以Dipyridamole治療後,發現在腎絲球PAS score和TGF-β表現有明顯的減少。 Heme-oxygenase-1(HO-1)是一種生理性壓力指標,Thy-1抗體所引起的HO-1表現會增加,在Dipyridamole治療後也會受到抑制。Osteopontin(OPN) 是一種bone sialoprotein,也曾被報導和腎臟纖維化有關。我們研究了OPN 在Thy-1抗體引發的腎炎所扮演的功能,發現OPN是一種組織的組成物質,於正常腎臟的腎小管、鮑氏囊體、及亨利氏環均有存在。施打anti-Thy-1抗體後於腎小管位置OPN有顯著的增加,但在絲球體卻沒有發現。所以,OPN不是和Thy-1產生的腎炎及腎纖維化有相關性。本實驗所使用Dipyridamole治療由Thy-1引起的OPN表現,於腎小管位置有發現受到抑制,但於腎小球沒有發現。綜合以上的報告,Dipyridamole 治療由anti-Thy-1引起的腎絲球腎炎蛋白尿,具有抑制的功效。
Anti-thy1 antibody-induced glomerular nephritis is a well established animal model for Mesangial cell proliferative glomeruli nephritis. Dipyridamole is a phosphodiesterase inhibitor, which has been shown to reduce GN-associated proteinurea. However, the detail mechanisms by which dipyridamole exert its therapeutic effects has not been elucidated. In the present study, we investigate the effect of dipyridamole on anti-thy1 -induced glomerular nephritis. We found that injection of anti-thy1 antibody resulted in acute glomerular nephritis (GN), characterized with massive proteinurea, increased of ED(+) macrophage infiltration and moderate PCNA(+) cell proliferation. These effects were all inhibited by treatment of rats with dipyridamole (5mg/Kg). TGF-βhas been shown to play an important role in extracellular matrix secretion. We next examined whether treatment of dipyridamole exerted beneficial effects on glomerular TGF-β expression and extracellular matrix accumulation. Injection of anti-thy1 antibody resulted in a mild increase of glomerular TGF-β and extracellular matrix accumulation as revealed by increased PAS score. Treatment of GN rats with dipyridamole significantly reduced the PAS score and TGF-β expresseion levels in glomeruli. Thy-1 antibody induced the expression of hem-oxygenase-1 (HO-1), a stress-induced marker, and the HO-1 induction was inhibited by treatment of rats with dipyridamole. Osteopontin, a bone sialoprotein, has been linked to renal fibrosis. I next investigate whether osteopontin (OPN) plays a role in anti Thy1 Ab-induced GN. OPN was constitutively expressed in tubules, Bowman’s capsule, and glomerular tuft of normal kidney. Injection of anti-thy1 antibody increased OPN expression in renal tubules but not in glomeruli, suggesting OPN was not associated with thy1-induced GN and subsequent renal fibrosis. Treatment of cells with dipyridamole reduced thy1-antibody stimulated OPN expression in renal tubule, but has little effect on glomerular OPN expression. Taken together, our results demonstrated that dipyridamole exhibited beneficial effects on thy-1 antibody induced GN.
目 錄
論文摘要..................................................................................................................I
Abstract ................................................................................................................III
目 錄 …………………………………………………………….............V
圖目 錄 ..............................................................................................................VII
縮 寫 表……………………………………………………………….......IV
第一章 緒 論..........................................................................................................1
1-1、Anti-Thy-1.1 Glomerulonephritis之介紹 .7
1-2、Dipyridamole之介紹 11
1-2.1、PDEI(phosphodiesterase inhibitor) 與疾病的關係………......14
1-2.1.1 PEDI與氣喘的關係 .......................................................................14
1-2.1.2 PEDI與纖維性囊腫的關係 ……………………………….......14
1-2.1-3PEDI與心臟衰竭的關係 15
1-2.1-4PEDI與腎臟病的關係 ................................................................. ..15
1-3 血紅素氧化酵素 ( Heme oxgenase, HO ) 之介紹.................................15
1-3.1 HO之 介 紹…………......................................................................16
1-3.2 HO-1 的特性及生理作用.................................................................16
1-4 活化性氧分子 (Reactive oxygen species ;ROS) 之介紹…………..17
1-5 相 關 文 獻 之 回 顧……………………………................................18
1-6 研 究 動 機 與 目 的…………………………………………..........20
第二章 實驗材料與方法………………………………………………....22
2-1 實驗藥品 24
2-2 常用儀器 24
2-3 常用溶液 25
2-4 實驗方法 ……………………………………………………..............26
2-4.1 Anti-Thy-1.1 Nephritis 動物模式之建立............................................26
2-4.1-1 前治療 ( pre-treatment ) 動物模式之建立 ..........................26
2-4.1-2 施行Anti-Thy-1,1 抗體注射.........................................................26
2-4.1-3 RNA萃取及病理切片處理 ...........................................................27
2-4.2 絲球體蛋白質的定…………………………………………….....28.
2-4.3 蛋 白 尿 及 其 他 生 化 檢 查…………………………..........29
2-4.4 H&E , PAS病 理 染 色 ………………………………...............29
2-4.5 Immunohistochemistry staining………………………..........29
2-5 統計分析.....................................................................................................30
第三章 結 果………………………………………………….................31
第四章 討 論 36
第五章 參 考 文 獻 41
第六章 實 驗 結 果 圖 表...............................................................................47
第七章 附 圖....................................................................................................73
參 考 文 獻

Adler, S., and Brady, H. R. (1999). Cell adhesion molecules and the glomerulopathies. Am J Med 107, 371-386.
Agarwal, A., Balla, J., Alam, J., Croatt, A. J., and Nath, K. A. (1995). Induction of heme oxygenase in toxic renal injury: a protective role in cisplatin nephrotoxicity in the rat. Kidney Int 48, 1298-1307.
Baeuerle, P. A., and Baltimore, D. (1996). NF-kappa B: ten years after. Cell 87, 13-20.
Brown, K., Gerstberger, S., Carlson, L., Franzoso, G., and Siebenlist, U. (1995). Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science 267, 1485-1488.
Burnouf, C., and Pruniaux, M. P. (2002). Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Des 8, 1255-1296.
Camara, S., de la Cruz, J. P., Frutos, M. A., Sanchez, P., Lopez de Novales, E., Sanchez, E., and Sanchez de la Cuesta, F. (1991). Effects of dipyridamole on the short-term evolution of glomerulonephritis. Nephron 58, 13-16.
Choi, A. M., and Alam, J. (1996). Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Am J Respir Cell Mol Biol 15, 9-19.
Datta, P. K., Koukouritaki, S. B., Hopp, K. A., and Lianos, E. A. (1999). Heme oxygenase-1 induction attenuates inducible nitric oxide synthase expression and proteinuria in glomerulonephritis. J Am Soc Nephrol 10, 2540-2550.
Denhardt, D. T., and Guo, X. (1993). Osteopontin: a protein with diverse functions. Faseb J 7, 1475-1482.
Engelbrecht, Y., de Wet, H., Horsch, K., Langeveldt, C. R., Hough, F. S., and Hulley, P. A. (2003). Glucocorticoids induce rapid up-regulation of mitogen-activated protein kinase phosphatase-1 and dephosphorylation of extracellular signal-regulated kinase and impair proliferation in human and mouse osteoblast cell lines. Endocrinology 144, 412-422.
FitzGerald, G. A. (1987). Dipyridamole. N Engl J Med 316, 1247-1257.
Gaertner, S. A., Janssen, U., Ostendorf, T., Koch, K. M., Floege, J., and Gwinner, W. (2002). Glomerular oxidative and antioxidative systems in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol 13, 2930-2937.
Gauer, S., Yao, J., Schoecklmann, H. O., and Sterzel, R. B. (1997). Adhesion molecules in the glomerular mesangium. Kidney Int 51, 1447-1453.
Gibbs, C. R., and Lip, G. Y. (1998). Do we still need dipyridamole? Br J Clin Pharmacol 45, 323-328.
Giembycz, M. A. (2000). Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs 59, 193-212.
Haas, C. S., Schocklmann, H. O., Lang, S., Kralewski, M., and Sterzel, R. B. (1999). Regulatory mechanism in glomerular mesangial cell proliferation. J Nephrol 12, 405-415.
Haberstroh, U., Pocock, J., Gomez-Guerrero, C., Helmchen, U., Hamann, A., Gutierrez-Ramos, J. C., Stahl, R. A., and Thaiss, F. (2002). Expression of the chemokines MCP-1/CCL2 and RANTES/CCL5 is differentially regulated by infiltrating inflammatory cells. Kidney Int 62, 1264-1276.
Harmankaya, O., Basturk, T., Ozturk, Y., Karabiber, N., and Obek, A. (2001). Effect of acetylsalicylic acid and dipyridamole in primary membranoproliferative glomerulonephritis type I. Int Urol Nephrol 33, 583-587.
Hewitson, T. D., Tait, M. G., Kelynack, K. J., Martic, M., and Becker, G. J. (2002). Dipyridamole inhibits in vitro renal fibroblast proliferation and collagen synthesis. J Lab Clin Med 140, 199-208.
Hung, K. Y., Shyu, R. S., Fang, C. C., Tsai, C. C., Lee, P. H., Tsai, T. J., and Hsieh, B. S. (2001). Dipyridamole inhibits human peritoneal mesothelial cell proliferation in vitro and attenuates rat peritoneal fibrosis in vivo. Kidney Int 59, 2316-2324.
Jefferson, J. A., and Johnson, R. J. (1999). Experimental mesangial proliferative glomerulonephritis (the anti-Thy-1.1 model). J Nephrol 12, 297-307.
Juckett, M. B., Balla, J., Balla, G., Jessurun, J., Jacob, H. S., and Vercellotti, G. M. (1995). Ferritin protects endothelial cells from oxidized low density lipoprotein in vitro. Am J Pathol 147, 782-789.
Kassel, O., Sancono, A., Kratzschmar, J., Kreft, B., Stassen, M., and Cato, A. C. (2001). Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. Embo J 20, 7108-7116.
Klahr, S., Schreiner, G., and Ichikawa, I. (1988). The progression of renal disease. N Engl J Med 318, 1657-1666.
Lasa, M., Abraham, S. M., Boucheron, C., Saklatvala, J., and Clark, A. R. (2002). Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol 22, 7802-7811.
Lenz, T. L., and Hilleman, D. E. (2000). Aggrenox: a fixed-dose combination of aspirin and dipyridamole. Ann Pharmacother 34, 1283-1290.
Liaw, L., Lindner, V., Schwartz, S. M., Chambers, A. F., and Giachelli, C. M. (1995). Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Circ Res 77, 665-672.
Loher, F., Schmall, K., Freytag, P., Landauer, N., Hallwachs, R., Bauer, C., Siegmund, B., Rieder, F., Lehr, H. A., Dauer, M., et al. (2003). The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice. J Pharmacol Exp Ther 305, 549-556.
Malinin, N. L., Boldin, M. P., Kovalenko, A. V., and Wallach, D. (1997). MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 385, 540-544.
Matsumori, A., Nunokawa, Y., and Sasayama, S. (2000). Pimobendan inhibits the activation of transcription factor NF-kappaB: a mechanism which explains its inhibition of cytokine production and inducible nitric oxide synthase. Life Sci 67, 2513-2519.
Mishra, R., Leahy, P., and Simonson, M. S. (2003). Gene expression profile of endothelin-1-induced growth in glomerular mesangial cells. Am J Physiol Cell Physiol 285, C1109-1115.
Moncada, S., and Korbut, R. (1978). Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1, 1286-1289.
Morimoto, K., Ohta, K., Yachie, A., Yang, Y., Shimizu, M., Goto, C., Toma, T., Kasahara, Y., Yokoyama, H., Miyata, T., et al. (2001). Cytoprotective role of heme oxygenase (HO)-1 in human kidney with various renal diseases. Kidney Int 60, 1858-1866.
Nath, K. A., Balla, G., Vercellotti, G. M., Balla, J., Jacob, H. S., Levitt, M. D., and Rosenberg, M. E. (1992). Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat. J Clin Invest 90, 267-270.
Pichler, R., Giachelli, C. M., Lombardi, D., Pippin, J., Gordon, K., Alpers, C. E., Schwartz, S. M., and Johnson, R. J. (1994). Tubulointerstitial disease in glomerulonephritis. Potential role of osteopontin (uropontin). Am J Pathol 144, 915-926.
Rittling, S. R., and Denhardt, D. T. (1999). Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp Nephrol 7, 103-113.
Ruiz-Ortega, M., Lorenzo, O., Ruperez, M., Esteban, V., Mezzano, S., and Egido, J. (2001). Renin-angiotensin system and renal damage: emerging data on angiotensin II as a proinflammatory mediator. Contrib Nephrol, 123-137.
Schlondorff, D. (1987). The glomerular mesangial cell: an expanding role for a specialized pericyte. Faseb J 1, 272-281.
Schreiner, G. F. (1992). The mesangial phagocyte and its regulation of contractile cell biology. J Am Soc Nephrol 2, S74-82.
Segerer, S., Nelson, P. J., and Schlondorff, D. (2000). Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 11, 152-176.
Senger, D. R., Perruzzi, C. A., Papadopoulos-Sergiou, A., and Van de Water, L. (1994). Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol Biol Cell 5, 565-574.
Sha, W. C. (1998). Regulation of immune responses by NF-kappa B/Rel transcription factor. J Exp Med 187, 143-146.
Shankland, S. J., Hugo, C., Coats, S. R., Nangaku, M., Pichler, R. H., Gordon, K. L., Pippin, J., Roberts, J. M., Couser, W. G., and Johnson, R. J. (1996). Changes in cell-cycle protein expression during experimental mesangial proliferative glomerulonephritis. Kidney Int 50, 1230-1239.
Shimizu, H., Takahashi, T., Suzuki, T., Yamasaki, A., Fujiwara, T., Odaka, Y., Hirakawa, M., Fujita, H., and Akagi, R. (2000). Protective effect of heme oxygenase induction in ischemic acute renal failure. Crit Care Med 28, 809-817.
Singh, R. P., Patarca, R., Schwartz, J., Singh, P., and Cantor, H. (1990). Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo. J Exp Med 171, 1931-1942.
Stawowy, P., Goetze, S., Margeta, C., Fleck, E., and Graf, K. (2003). LPS regulate ERK1/2-dependent signaling in cardiac fibroblasts via PKC-mediated MKP-1 induction. Biochem Biophys Res Commun 303, 74-80.
Stocker, R. (1990). Induction of haem oxygenase as a defence against oxidative stress. Free Radic Res Commun 9, 101-112.
Tang, W. W., Yin, S., Wittwer, A. J., and Qi, M. (1995). Chemokine gene expression in anti-glomerular basement membrane antibody glomerulonephritis. Am J Physiol 269, F323-330.
Teixeira, M. M., Gristwood, R. W., Cooper, N., and Hellewell, P. G. (1997). Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol Sci 18, 164-171.
Thom, S. R., Fisher, D., Xu, Y. A., Notarfrancesco, K., and Ischiropoulos, H. (2000). Adaptive responses and apoptosis in endothelial cells exposed to carbon monoxide. Proc Natl Acad Sci U S A 97, 1305-1310.
Veis, J. H. (1993). An overview of mesangial cell biology. Contrib Nephrol 104, 115-126.
Weber, G. F., and Cantor, H. (1996). The immunology of Eta-1/osteopontin. Cytokine Growth Factor Rev 7, 241-248.
Wu, X., Dolecki, G. J., Sherry, B., Zagorski, J., and Lefkowith, J. B. (1997). Chemokines are expressed in a myeloid cell-dependent fashion and mediate distinct functions in immune complex glomerulonephritis in rat. J Immunol 158, 3917-3924.
Yu, X. Q., Nikolic-Paterson, D. J., Mu, W., Giachelli, C. M., Atkins, R. C., Johnson, R. J., and Lan, H. Y. (1998). A functional role for osteopontin in experimental crescentic glomerulonephritis in the rat. Proc Assoc Am Physicians 110, 50-64.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
1. 周新富(1998)。提高家長參與子女學習的有效途徑。人文及社會學科教學通訊,9(3),162-172。
2. 林明地(1996)。學校與社區關係-從家長參與學校活動的理念談起。教育研究雙月刊,51,30-39。
3. 林初穗(2002)。桃園縣早期療育服務執行成效研究。中原學報,13(4),489-504。
4. 周文麗、鄭麗珍、林惠芳(2000)。台灣早期療育的發展與未來展望。文教新潮,5(4),7-12。
5. 何東墀(2003)。特殊教育發展中家長參與的催化功能。特教園丁,19(2),1-7。
6. 任秀媚(1985)。家長參與幼兒學校學習活動對幼兒社會行為的影響。新竹師專學報,12,125-180。
7. 江民瑜、黃蕙君、林俊瑩(2005)。國小學生家長參與學校教育之性別差異:以高雄縣市為例。教育與社會研究,8,81-114。
8. 王國羽(1996)。身心障礙兒童早期療育政策的相關理論模式與台灣法令之解析。東吳社會工作學報,2,333-350。
9. 王天苗(1996)。台灣地區心智障礙幼兒早期療育服務供需及相關問題研究。特殊教育研究學刊,14,21-44。
10. 林義男(1993)。國中學生家庭社經背景、父母參與及其學業成就的關係。輔導學報,16,157-212。
11. 張世慧(1996)。臺北市學前障礙幼兒家庭需求之調查研究。國小特殊教育,20,7-20。
12. 陳明聰、王天苗(1997)。臺北市國小啟智班學生父母參與之研究。特殊教育研究學刊,15,215-235。
13. 陳惠茹(2004)。特殊教育專業整合中的家長參與。特教園丁,19(3),1-6。
14. 劉慶仁(2000)。談學校推動父母參與教育。教師天地,104,22-27。
15. 劉曉娟、林惠芬(2003)。中部地區國中啟智班家長參與個別化教育計畫會議之研究。特殊教育學報,18,1-19。